α干扰素和利巴韦林抗丙型肝炎病毒作用的比较研究

摘要

α干扰素(IFN-α)联合利巴韦林是目前临床治疗丙型肝炎病毒(HCV)感染的标准方案.本研究以体外培养的感染性病毒HCVcc为研究对象,比较IFN-α和利巴韦林对HCV复制的影响,以及对干扰素调节因子9(IRF9)和干扰素刺激基因15(ISG15)等抗病毒基因的调节能力.结果显示,100 u/ml IFN-α显著降低HCV RNA水平,利巴韦林剂量依赖性抑制HCV复制,且IFN-α联合利巴韦林对HCV复制及HCV NS3和E2蛋白表达具有协同抑制作用.5～80 u/ml IFN-α剂量依赖性诱生IRF9和ISG15;1和5μg/ml利巴韦林不促进IRF9和ISG15水平升高；而利巴韦林联合IFN-α对两者亦无促进作用.%The current standard therapy for hepatitis C virus (HCV) infection consists of a combination of interferon α (IFN-α) and ribavirin. In this study, the effects of IFN-α and ribavirin on HCV replication as well as antiviral genes were examined. The results showed that 100 u/ml IFN-α significantly reduced HCV RNA level. Ribavirin inhibited HCV replication in a dose-dependent manner and ribavirin in combination with IFN-α exhibited synergetic inhibitory effect on HCV replication, and NS3 and E2 protein expressions. IFN-α increased the levels of IFN regulatory factor 9 (IRF9) and IFN-stimulated gene 15 (ISG15) in a dose-dependent manner. However, 1 and 5 jug/ml ribavirin had no such effects on the IRF9 and ISG15 induction.